BioMarin Pharmaceutical (NASDAQ:BMRN) saw a 19% jump in shares after announcing a $4.8 billion all-cash deal to acquire Amicus Therapeutics. The deal valued Amicus at $14.50 per share, a 33% premium. This move expands BioMarin’s rare disease portfolio with two new treatments, boosting revenue growth and earnings per share. Both boards approved the deal, signaling strong support. The shares closed at $61.19, up 17.8%. BioMarin Pharmaceutical’s stock is not very volatile, with only 5 moves greater than 5% in the past year. This news significantly impacted market perception, with the stock down 8% since the beginning of the year.

Read more at Stockstory.org’s media company name is “Barchart”.: Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today